Incretins: Clinical Physiology And Bariatric Surgery - Correlating The Entero-endocrine System And A Potentially Anti-dysmetabolic Procedure

dc.creatorLamounier R.N.
dc.creatorPareja J.C.
dc.creatorTambascia M.A.
dc.creatorGeloneze B.
dc.date2007
dc.date2015-06-30T18:48:52Z
dc.date2015-11-26T14:36:46Z
dc.date2015-06-30T18:48:52Z
dc.date2015-11-26T14:36:46Z
dc.date.accessioned2018-03-28T21:40:48Z
dc.date.available2018-03-28T21:40:48Z
dc.identifier
dc.identifierObesity Surgery. , v. 17, n. 5, p. 569 - 576, 2007.
dc.identifier9608923
dc.identifier10.1007/s11695-007-9098-y
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-34250617485&partnerID=40&md5=efc2f18174652723e8073638d3d6b011
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/104908
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/104908
dc.identifier2-s2.0-34250617485
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1248887
dc.descriptionThe digestive tract is well known for its endocrine functions. Recently, many studies have been reinforcing its role as a therapeutic target for both diabetes and obesity. Losing weight is clinically very difficult for most obese patients and the reason for this could be the effect of the physiological adipostatic system that triggers central nervous stimuli to compensate for variations in food intake and in physical activity. Gut hormones seem to have a key role in this complex, regulating body weight and satiety and contributing to glucose homeostasis. The enteroinsular axis appears to be impaired in both obese and diabetic patients. Recent data on bariatric surgery shows its striking effects on glucose control soon after the procedure, before a significant weight loss is achieved. The procedure appears to work beyond anti-obesity having a key metabolic impact possibly sharing a common mechanism with the new class of agents to treat type 2 diabetes mellitus: the incretin mimetics.This symposium discussed new data on the upcoming perspectives on both the pharmacological and the surgical approach to diabetes and obesity. © 2007 Springer Science + Business Media B.V.
dc.description17
dc.description5
dc.description569
dc.description576
dc.descriptionMeier, J.J., Nauck, M.A., Schmidt, W.E., Gastric inhibitory polypeptide: The neglected incretin revisited (2002) Regul Pept, 107, pp. 1-13
dc.descriptionCreutzfeldt, W., Entero-insular axis and diabetes mellitus (1992) Horm Metab Res Suppl, 26, pp. 13-18
dc.descriptionGutniak, M., Orskov, C., Holst, J.J., Antidiabetogenic effect of glucagon-like peptide-1 (7-36) amide in normal subjects and patients with diabetes mellitus (1992) N Engl J Med, 326, pp. 1316-1322
dc.descriptionMeier, J.J., Hucking, K., Holst, J.J., Reduced insulinotropic effect of gastric inhibitory polypeptide in first-degree relatives of patients with type 2 diabetes (2001) Diabetes, 50, pp. 2404-2497
dc.descriptionMeier, J.J., Gallwitz, B., Salmen, S., Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes (2003) J Clin Endocrinol Metab, 88, pp. 2719-2725
dc.descriptionPatriti, A., Facchiano, E., Sanna, A., The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery (2004) Obes Surg, 14, pp. 840-848
dc.descriptionPowley, T.L., Phillips, R.J., Gastric satiation is volumetric, intestinal satiation is nutritive (2004) Physiol Behav, 82, pp. 69-74
dc.descriptionCummings, D.E., Purnell, J.Q., Frayo, R., A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans (2001) Diabetes, 50, pp. 1714-1719
dc.descriptionMundinger, T.O., Cummings, D.E., Taborsky Jr., G.J., Direct stimulation of ghrelin secretion by sympathetic nerves (2006) Endocrinology, 147, pp. 2893-2901
dc.descriptionCummings, D.E., Clement, K., Purnell, J.Q., Elevated plasma ghrelin levels in Prader-Willi syndrome (2002) Nat Med, 8, pp. 643-644
dc.descriptionXu, G., Kaneto, H., Lopez-Avalos, M.D., GLP-1/exendin-4 facilitates beta-cell neogenesis in rat and human pancreatic ducts (2006) Diab Res Clin Pract, 73, pp. 107-110
dc.descriptionService, G.J., Thompson, G.B., Service, F.J., Hyperinsulinemic hypoglycemia with nesidioblastosis after gastric-bypass surgery (2005) N Engl J Med, 353, pp. 249-254
dc.descriptionFung, M., Thompson, D., Shapiro, R.J., Effect of glucagonlike peptide-1 (7-37) on beta-cell function after islet transplantation in type 1 diabetes (2006) Diab Res Clin Pract, 74, pp. 189-193
dc.descriptionDrucker, D.J., Biological actions and therapeutic potential of the glucagon-like peptides (2002) Gastroenteroloy, 122, pp. 531-544
dc.descriptionGautier, J.F., Fetita, S., Sobngwi, E., Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes (2005) Diab Metab, 31, pp. 233-242
dc.descriptionMunzberg, H., Myers Jr., M.G., Molecular and anatomical determinants of central leptin resistance (2005) Nat Neurosci, 8, pp. 566-570
dc.descriptionDe Souza, C.T., Araujo, E.P., Bordin, S., Consumption of a fat-rich diet activates a proinflammatory response and induces insulin resistance in the hypothalamus (2005) Endocrinology, 146, pp. 4192-4199
dc.descriptionTurton, M.D., O'Shea, D., Gunn, I., A role for glucagonlike peptide-1 in the central regulation of feeding (1996) Nature, 379, pp. 69-72
dc.descriptionHansotia, T., Baggio, L.L., Delmeire, D., Double incretin receptor knockout (DIRKO) mice reveal an essential role for the enteroinsular axis in transducing the glucoregulatory actions of DPP-IV inhibitors (2004) Diabetes, 53, pp. 1326-1335
dc.descriptionYamamoto, H., Lee, C.E., Marcus, J.N., Glucagon-like peptide- 1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons (2002) J Clin Invest, 110, pp. 43-52
dc.descriptionNystrom, T., Gutniak, M.K., Zhang, Q., Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease (2004) Am J Physiol Endocrinol Metab, 287, pp. 1209-E1215
dc.descriptionNikolaidis, L.A., Elahi, D., Hentosz, T., Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy (2004) Circulation, 110, pp. 955-961
dc.descriptionNikolaidis, L.A., Mankad, S., Sokos, G.G., Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion (2004) Circulation, 109, pp. 962-965
dc.descriptionYu, M., Moreno, C., Hoagland, K.M., Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats (2003) J Hypertens, 21, pp. 1125-1135
dc.descriptionMeier, J.J., Gallwitz, B., Askenas, M., Secretion of incretin hormones and the insulinotropic effect of gastric inhibitory polypeptide in women with a history of gestational diabetes (2005) Diabetologia, 48, pp. 1872-1881
dc.descriptionNyholm, B., Walker, M., Gravholt, C.H., Twenty-four-hour insulin secretion rates, circulating concentrations of fuel substrates and gut incretin hormones in healthy offspring of Type II (non-insulin-dependent) diabetic parents: Evidence of several aberrations (1999) Diabetologia, 42, pp. 1314-1323
dc.descriptionSchou, J.H., Pilgaard, K., Vilsbøll, T., Normal secretion and action of the gut incretin hormones glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide in young men with low birth weight (2005) J Clin Endocrinol Metab, 90, pp. 4912-4919
dc.descriptionAnini, Y., Brubaker, P.L., Role of leptin in the regulation of glucagon-like peptide-1 secretion (2003) Diabetes, 52, pp. 252-259
dc.descriptionVilsbøll, T., Knop, F.K., Krarup, T., The pathophysiology of diabetes involves a defective amplification of the latephase insulin response to glucose by glucose-dependent insulinotropic polypeptide - Regardless of etiology and phenotype (2003) J Clin Endocrinol Metab, 88, pp. 4803-4897
dc.descriptionLugari, R., Dei Cas, A., Ugolotti, D., Glucagon-like peptide 1 (GLP-1) secretion and plasma dipeptidyl peptidase IV (DPP-IV) activity in morbidly obese patients undergoing biliopancreatic diversion (2004) Horm Metab Res, 36, pp. 111-115
dc.descriptionRyskjaer, J., Deacon, C.F., Carr, R.D., Plasma dipeptidyl peptidase- IV activity in patients with type-2 diabetes mellitus correlates positively with HbAlc levels, but is not acutely affected by food intake (2006) Eur J Endocrinol, 155, pp. 485-493
dc.descriptionGreen, B.D., Irwin, N., Duffy, N.A., Inhibition of dipeptidyl peptidase-IV activity by metformin enhances the antidiabetic effects of glucagon-like peptide-1 (2006) Eur J Pharmacol, 547, pp. 192-199
dc.descriptionDefronzo, R.A., Ratner, R.E., Han, J., Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes (2005) Diabetes Care, 28, pp. 1092-1100
dc.descriptionBuse, J.B., Henry, R.R., Han, J., Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea- treated patients with type 2 diabetes (2004) Diabetes Care, 27, pp. 2628-2635
dc.descriptionKendall, D.M., Riddle, M.C., Rosenstock, J., Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea (2005) Diabetes Care, 28, pp. 1083-1091
dc.descriptionHeine, R.J., Van Gaal, L.F., Johns, D., Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: A randomized trial (2005) Ann Intern Med, 143, pp. 559-569
dc.descriptionMadsbad, S., Schmitz, O., Ranstam, J., Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): A 12- week, double-blind, randomized, controlled trial (2004) Diabetes Care, 27, pp. 1335-1342
dc.descriptionBarnett, A., DPP-4 inhibitors and their potential role in the management of type 2 diabetes (2006) Int J Clin Pract, 60, pp. 1454-1470
dc.descriptionNielsen, L.L., Young, A.A., Parkes, D.G., Pharmacology of exenatide (synthetic exendin-4): A potential therapeutic for improved glycemic control of type 2 diabetes (2004) Regul Pept, 117, pp. 77-88
dc.descriptionFineman, M.S., Bicsak, T.A., Shen, L.Z., Effect on glycemic control of exenatide (synthetic Exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes (2003) Diabetes Care, 26, pp. 2370-2377
dc.descriptionKolterman, O.G., Buse, J.B., Fineman, M.S., Synthetic Exendin-4 (Exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes (2003) J Clin Endocrinol Metab, 88, pp. 3082-3089
dc.descriptionFehse, F., Trautmann, M., Holst, J.J., Exenatide augments first- and second-phase insulin secretion in response to intravenous glucose in subjects with type 2 diabetes (2005) J Clin Endocrinol Metab, 90, pp. 5991-5997
dc.descriptionStoffers, D.A., Kieffer, T.J., Hussain, M.A., Insulinotropic glucagon-like peptide 1 agonists stimulate expression of homeodomain protein IDX-1 and increase islet size in mouse pancreas (2000) Diabetes, 49, pp. 741-748
dc.descriptionHerman, G.A., Bergman, A., Stevens, C., Effect of single oral doses of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on incretin and plasma glucose levels after an oral glucose tolerance test in patients with type 2 diabetes (2006) J Clin Endocrinol Metab, 91, pp. 4612-4619
dc.descriptionNauck, M.A., Meininger, G., Sheng, D., Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: A randomized, double-blind, non-inferiority trial (2007) Diab Obes Metab, 9, pp. 194-205
dc.descriptionRosenstock, J., Brazg, R., Andryuk, P.J., Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: A 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study (2006) Clin Ther, 28, pp. 1556-1568
dc.descriptionRosenstock, J., Baron, M.A., Dejager, S., Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes (2007) Diabetes Care, 30, pp. 217-223
dc.descriptionMari, A., Sallas, W.M., He, Y.L., Vildagliptin, a dipeptidyl peptidase-IV inhibitor, improves model-assessed beta-cell function in patients with type 2 diabetes (2005) J Clin Endocrinol Metab, 90, pp. 4888-4894
dc.descriptionAhrén, B.O., Landin-Olsson, M., Jansson, P.A., Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes (2004) J Clin Endocrinol Metab, 89, pp. 2078-2084
dc.descriptionSjöström, L., Lindroos, A.K., Peltonen, M., Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery (2004) N Engl J Med, 351, pp. 2683-2693
dc.descriptionCummings, D.E., Weigle, D.S., Frayo, R.S., Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery (2002) N Engl J Med, 346, pp. 1623-1630
dc.descriptionGeloneze, B., Tambascia, M.A., Pilla, V.F., Ghrelin: A gutbrain hormone: Effect of gastric bypass surgery (2003) Obes Surg, 13, pp. 17-22
dc.descriptionFruhbeck, G., Rotellar, F., Hernandez-Lizoain, J.L., Fasting plasma ghrelin concentrations 6 months after gastric bypass are not determined by weight loss or changes in insulinemia (2004) Obes Surg, 14, pp. 1208-1215
dc.descriptionStoeckli, R., Chanda, R., Langer, I., Changes of body weight and plasma ghrelin levels after gastric banding and gastric bypass (2004) Obes Res, 12, pp. 346-350
dc.descriptionKorner, J., Bessler, M., Cirilo, L.J., Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial concentrations of plasma ghrelin, peptide YY, and insulin (2005) J Clin Endocrinol Metab, 90, pp. 359-365
dc.descriptionMorínigo, R., Moizé, V., Musri, M., Glucagon-like peptide- 1, peptide YY, hunger, and satiety after gastric bypass surgery in morbidly obese subjects (2006) J Clin Endocrinol Metab, 91, pp. 1735-1740
dc.descriptionMarinari, G.M., Papadia, F.S., Briatore, L., Type 2 diabetes and weight loss following biliopancreatic diversion for obesity (2006) Obes Surg, 16, pp. 1440-1445
dc.descriptionGuidone, C., Manco, M., Valera-Mora, E., Mechanisms of recovery from type 2 diabetes after malabsorptive bariatric surgery (2006) Diabetes, 55, pp. 2025-2031
dc.descriptionStrader, A.D., Vahl, T.P., Jandacek, R.J., Weight loss through ileal transposition is accompanied by increased ileal hormone secretion and synthesis in rats (2005) Am J Physiol Endocrinol Metab, 288, pp. 447-E453
dc.descriptionRubino, F., Forgione, A., Cummings, D.E., The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes (2006) Ann Surg, 244, pp. 741-749
dc.descriptionGumbs, A.A., Modlin, I.M., Ballantyne, G.H., Changes in insulin resistance following bariatric surgery: Role of caloric restriction and weight loss (2005) Obes Surg, 15, pp. 462-473
dc.descriptionBallantyne, G.H., Peptide YY(1-36) and peptide YY(3-36): Part II. Changes after gastrointestinal surgery and bariatric surgery (2006) Obes Surg, 16, pp. 703-795
dc.descriptionBallantyne, G.H., Farkas, D., Laker, S., Short-term changes in insulin resistance following weight loss surgery for morbid obesity: Laparoscopic adjustable gastric banding versus laparoscopic Roux-en-Y gastric bypass (2006) Obes Surg, 16, pp. 1189-1197
dc.descriptionPitombo, C., Araujo, E.P., De Souza, C.T., Amelioration of diet-induced diabetes mellitus by removal of visceral fat (2006) J Endocrinol, 191, pp. 699-706
dc.descriptionThörne, A., Lönnqvist, F., Apelman, J., A pilot study of long-term effects of a novel obesity treatment: Omentectomy in connection with adjustable gastric banding (2002) Int J Obes, 26, pp. 193-199
dc.descriptionDe Paula, A.L., MacEdo, A.L., Prudente, A.S., Laparoscopic sleeve gastrectomy with ileal interposition ("neuroendocrine brake")-pilot study of a new operation (2006) Surg Obes Relat Dis, 2, pp. 464-467
dc.languageen
dc.publisher
dc.relationObesity Surgery
dc.rightsfechado
dc.sourceScopus
dc.titleIncretins: Clinical Physiology And Bariatric Surgery - Correlating The Entero-endocrine System And A Potentially Anti-dysmetabolic Procedure
dc.typeActas de congresos


Este ítem pertenece a la siguiente institución